THanks a lot for your comments. Yes, I'm sure it is low cluster density, I can see it at the thumbnails and comparing to other runs. We only got like 200K clusters...that is really low
-
Hi there,
THanks a lot for your comments. Yes, I'm sure it is low cluster density, I can see it at the thumbnails and comparing to other runs. We only got like 200K clusters...that is really low
-
Are you sure that it really is low cluster density? Do you have access to the Thumbnails? When a flow cell is very overloaded it may falsely report a low cluster density. I ask because our experience with 16S/ITS amplicons on the MiSeq is that they need to be loaded at much lower concentrations (3.0pM). But this is with amplicon we make using the Schloss SOP. Amplicons prepared using a different protocol may require very different loading concentration.Leave a comment:
-
Anyone using QIAGEN 16S/ITS Panel with MiSeq?
Hi there!
Anyone using QIAGEN 16S/ITS Panel with MiSeq?
We have good libraries with good profiles, quantified by TapeStation, Qubit and qPCR and we load them according to Qiagen instructions (dilute to 2nM and load at 10pM) and it result in very low cluster density...NaOH is working properly with all the other runs, the Miseq is also giving good results with other type of Runs....anyone is in the same situation? Or anyone is having good results with this Panel sequencing on a MiSeq?
Thanks a lot in advance!
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Leave a comment: